



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Levetiracetam-d₆

Item No. 26457

CAS Registry No.: 1133229-30-7
Formal Name: αS-α-ethyl-5-oxo-1-pyrrolidine-2,2,3,3,4,4-d₆-acetamide
MF: C₈H₈D₆N₂O₂
FW: 176.2
Chemical Purity: ≥95% (Levetiracetam)
Deuterium
Incorporation: ≥99% deuterated forms (d₁-d₆); ≤1% d₀
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Levetiracetam-d₆ is intended for use as an internal standard for the quantification of levetiracetam (Item No. 9001820) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated *versus* unlabeled).

Levetiracetam-d₆ is supplied as a solid. A stock solution may be made by dissolving the levetiracetam-d₆ in the solvent of choice, which should be purged with an inert gas. Levetiracetam-d₆ is slightly soluble in acetone (sonicated) and chloroform.

Description

Levetiracetam is an antiepileptic agent that binds to the synaptic vesicle protein SV2A (IC₅₀ = 1.99 μM).¹ *In vivo*, levetiracetam suppresses seizures in fully kindled rats.²

References

1. Lynch, B.A., Lamberg, N., Nocka, K., *et al.* The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. *Proc. Nat. Acad. Sci. USA* **101**(26), 9861-9866 (2004).
2. Löscher, W. and Brandt, C. Prevention or modification of epileptogenesis after brain insults: Experimental approaches and translational research. *Pharmacol. Rev.* **62**(4), 668-700 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/26/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM